{
  "id": "5a7d5033faa1ab7d2e000015",
  "type": "yesno",
  "question": "Is davunetide being considered for the treatment of progressive supranuclear palsy?",
  "ideal_answer": "Yes, Davunetide's efficacy and tolerability are being tested in a placebo-controlled study in PSP patients.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22347799"
  ],
  "snippets": [
    {
      "text": "Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22347799",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Davunetide's efficacy and tolerability are being tested in a placebo-controlled study in PSP patients, making it the most advanced drug candidate in this indication. This review examines the disease characteristics of PSP, the rationale for treating PSP with davunetide and assesses some of the challenges of clinical trials in this patient population.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22347799",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}